Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 15NETWORK 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 14Radiotherapy 13Oxaliplatin 8Fluorouracil 7Gemcitabine 6Drug Therapy 6Leucovorin 5Doxorubicin 5Cytarabine 5Cyclophosphamide 5Carboplatin 5Capecitabine 5durvalumab 4Paclitaxel 4Etoposide 4Docetaxel 4Chemotherapy, Adjuvant 4Biological Therapy 4bicalutamide 3Rituximab 3Radiotherapy, Intensity-Modulated 3Polymerase Chain Reaction 3Platinum 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Gene Expression Profiling 3Dexamethasone 3Bortezomib 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × NETWORK × lenvatinib × Clear all
NCT06068153 2024-11-20

AMBER

ETOP IBCSG Partners Foundation

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03005015 2016-12-29

Lenvatinib in Second Line Endometrial Carcinoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡